HepatologyNews.net

Hepatology Xagena

Interferon-based treatment is not suitable for many patients with hepatitis C virus ( HCV ) infection because of contraindications such as psychiatric illness, and a high burden of adverse events. L ...


Interferon-containing regimens for the treatment of hepatitis C virus ( HCV ) infection are associated with increased toxic effects in patients who also have cirrhosis. Researchers have evaluated ...


Glycerol phenylbutyrate ( Ravicti ) lowers ammonia by providing an alternate pathway to urea for waste nitrogen excretion in the form of phenylacetyl glutamine, which is excreted in urine. A rando ...


The first detailed results from pivotal phase III study, PEARL-III, were presented as part of the 21st Conference on Retroviruses and Opportunistic Infections ( CROI ). PEARL-III evaluated the effica ...


Forty percent of patients with autoimmune hepatitis ( AIH ) present with acute jaundice / hepatitis. Such patients, when treated promptly, are thought to have a good prognosis. The objective of a s ...


Entecavir ( Baraclude ) is effective and safe in patients with chronic hepatitis B in the short term, but its long term efficacy and safety has not been established. Researchers have evaluated HBV ...


High rates of sustained virologic response were observed among patients with hepatitis C virus ( HCV ) infection who received 12 weeks of treatment with the nucleotide polymerase inhibitor Sofosbuvir ...


The Interferon-free combination of the protease inhibitor ABT-450 with Ritonavir ( ABT-450/r ) and the NS5A inhibitor Ombitasvir ( also known as ABT-267 ) plus the nonnucleoside polymerase inhibitor D ...


In phase 2 studies, treatment with the all-oral combination of the nucleotide polymerase inhibitor Sofosbuvir and the NS5A inhibitor Ledipasvir resulted in high rates of sustained virologic response a ...


Interferon-containing regimens for the treatment of hepatitis C virus ( HCV ) infection are associated with increased toxic effects in patients who also have cirrhosis. Researchers have evaluated th ...


In this phase 3 trial researchers have evaluated the efficacy and safety of the Interferon-free combination of ABT-450 with Ritonavir ( ABT-450/r ), Ombitasvir ( also known as ABT-267 ), Dasabuvir ( a ...


Effective treatment for hepatitis C virus ( HCV ) genotype 1 infection in patients who have not had a sustained virologic response to prior Interferon-based therapy represents an unmet medical need. ...


Results from a phase III study presented at the International Liver Congress 2014 have shown Obeticholic acid ( OCA ) given to patients suffering from primary biliary cirrhosis ( PBC ) who previously ...


The new Interferon-free, all-oral, three direct-acting-antiviral ( 3D ) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected ...


Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented at the International Liver Congress 2014 showed that Simeprevir ( Olysio )150 mg once-daily for 12 weeks in comb ...


In a study involving treatment-naive and treatment-experienced patients of Egyptian ancestry with chronic genotype 4 HCV infection, Sofosbuvir ( Sovaldi ) plus Ribavirin was shown to provide a simple, ...


Epidemiological, genetic and clinical data presented at the International Liver Congress 2014 are collectively focussed on different approaches designed to improve the diagnosis, staging and treatment ...


Low-dose oral Interferon could exert immune-modulating effects in human. Researchers have conducted a clinical trial to investigate the efficacy of oral Interferon-alpha in preventing hepatitis C rela ...


An Interferon-free combination of the protease inhibitor ABT-450 with Ritonavir ( ABT-450/r ), the nonnucleoside polymerase inhibitor ABT-333, and Ribavirin has showed efficacy against the hepatitis C ...


A phase III study has enrolled 217 patients with primary biliary cirrhosis who had either failed to get an adequate response with UDCA ( Ursodeoxycholic acid ), or had been unable to tolerate it. Pa ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati